The MicroIBioM study: the gut microbiome in inclusion body myositis
Authors' conclusion
General differences of gut microbiome seem unlikely to play a role in the genesis of IBM.
Study context
- Population
- Inclusion body myositis (IBM) patients and their unaffected spouses/cohabitants
- Participants
- 21 vs 20
- Comparison
- IBM patients vs unaffected spouses/cohabitants
- IBMn = 21
- Controln = 20reference
- Outcome
- Gut microbiome alpha and beta diversity
Methodological detailsunaffected spouses/cohabitants as controls, 16S rRNA V3V4 metagenomic analysis, Bioinformatic analyses with QIIME2 and MicrobiomeAnalyst; LEfSe and Random Forest for biomarkers; PICRUSt pathway analysis
- Unaffected spouses/cohabitants as controls
- 16S rRNA V3V4 metagenomic analysis
- Bioinformatic analyses with QIIME2 and MicrobiomeAnalyst; LEfSe and Random Forest for biomarkers; PICRUSt pathway analysis
Main finding
As reported in the abstract
Overall alpha and beta diversity
- No overall differences of alpha and beta diversity between IBM and control
Observational data: associations, not effects.
Further findings
Alpha diversity, older (≥ 72 years) probands (subgroup)
- Reduction in alpha diversity comparing older (≥ 72 years) IBM and control probands
Impact of immune treatments
- No impact of immune treatments found
Genus abundances and biomarkers
- Increased abundances of some genera, in particular Bacteroides, in IBM
- Bacteroides, Clostridium CAG 352 and Eggerthella identified as IBM biomarkers at genus level
Gastrointestinal symptoms vs disease severity
- Gastrointestinal symptoms (modified Gastrointestinal Symptom Rating Scale (mGSRS)) correlated with disease severity (IBM Functional Rating Scale (IBMFRS))
Original publication
The MicroIBioM study: the gut microbiome in inclusion body myositis. Clin Exp Rheumatol. Published 12 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →